8-K: United-Guardian Q3 Earnings Plunge on Cosmetic Sales Drop

United-Guardian, Inc. reported a significant decline in third-quarter and nine-month sales and net income for 2025, primarily due to reduced cosmetic ingredient purchases by its largest marketing partner, Ashland Specialty Ingredients.

Summary

• Third quarter 2025 sales decreased by 26% to $2,264,261 from $3,060,113 in Q3 2024.
• Third quarter 2025 net income decreased by 69% to $268,441 ($0.06 per share) from $865,484 ($0.19 per share) in Q3 2024.
• Nine-month 2025 sales decreased by 21.9% to $7,583,613 from $9,705,262 in the same period of 2024.
• Nine-month 2025 net income decreased by 47% to $1,456,162 ($0.32 per share) from $2,747,151 ($0.60 per share) in the same period of 2024.
• The decrease in sales was primarily attributed to reduced purchases of cosmetic ingredients by Ashland Specialty Ingredients (ASI), the company's largest marketing partner.
• Sales of pharmaceutical products increased by 10% and medical products increased by 6% during the first nine months of 2025 compared to the same period in 2024.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant declines in sales and net income for both the quarter and nine-month period. However, there are some positive future-oriented initiatives (Renacidin project, new marketing agreements) and an explanation for the decline (ASI issues) that prevent a lower score.

Positives

• Pharmaceutical product sales increased by 10% during the first nine months of 2025 compared to the same period in 2024.
• Medical product sales increased by 6% during the first nine months of 2025 compared to the same period in 2024.
• Progress has been made on a project to increase sales of Renacidin, a key pharmaceutical product, by working with an outside consultant to include it on additional drug formularies.
• New marketing agreements have been negotiated recently for some new personal care products, expected to contribute to future revenue growth.

Negatives

• Third quarter 2025 net sales decreased by 26% to $2,264,261 from $3,060,113 in Q3 2024.
• Third quarter 2025 net income decreased by 69% to $268,441 ($0.06 per share) from $865,484 ($0.19 per share) in Q3 2024.
• Nine-month 2025 net sales decreased by 21.9% to $7,583,613 from $9,705,262 in the same period of 2024.
• Nine-month 2025 net income decreased by 47% to $1,456,162 ($0.32 per share) from $2,747,151 ($0.60 per share) in the same period of 2024.
• A significant decrease in sales of cosmetic ingredients occurred in the third quarter, primarily due to reduced purchases by Ashland Specialty Ingredients (ASI).
• ASI's reduced purchases were caused by difficult tariff and geopolitical concerns in Asia, leading customers to lower-cost local products and ASI needing to work down excess inventory.

Risks

• Forward-looking statements are subject to factors that could cause actual results to differ materially from anticipated results.
• Difficult tariff and geopolitical concerns in Asia could continue to impact sales of cosmetic ingredients.
• Continued destocking by marketing partners like Ashland Specialty Ingredients could depress future orders.
• Customers moving towards lower-cost local products in response to market conditions could reduce demand for the company's cosmetic ingredients.

Future Outlook

Ashland Specialty Ingredients (ASI) has expressed confidence in its ability to regain market share by offering more competitive pricing in the future. The company is hopeful that its project to include Renacidin on additional drug formularies will significantly increase sales over the coming years. Additionally, new marketing agreements for personal care products are expected to provide an excellent opportunity to increase revenue in the coming years.

Management Comments

• "While sales of our pharmaceutical and medical products both increased during the first nine-months of 2025 compared with the same period in 2024 (increasing by 10% and 6%, respectively), we did experience a decrease in sales of our cosmetic ingredients in this year's third quarter compared with 2024."
• "That decrease was attributable primarily to reduced purchases of our cosmetic ingredients by Ashland Specialty Ingredients (ASI), our largest marketing partner, which has been dealing with difficult tariff and geopolitical concerns in Asia that have caused some customers to move towards lower cost local products."
• "This has resulted in ASI having to work down excess inventory, which has caused a decrease in their orders this year."
• "On a positive note we have made progress with our project to increase sales of Renacidin, our most important pharmaceutical product, by working with an outside pharmaceutical consultant to have Renacidin included on additional drug formularies."
• "We are excited about the potential this project has to significantly increase sales of Renacidin over the coming years."
• "We are hopeful that this project, along with the new marketing agreements we have negotiated recently for some of our new personal care products, will give us an excellent opportunity to increase our revenue in the coming years."

Industry Context

The company's performance, particularly the depressed sales of cosmetic ingredients, is consistent with recent reports indicating that sales and earnings of U.S. chemical companies in the third quarter were negatively impacted by weak China demand, continued destocking, and tariffs. This suggests broader industry headwinds affecting the chemical and specialty ingredients sector.

Comparison to Industry Standards

• No specific comparable companies, projects, or results were mentioned in the filing for direct comparison.
• The company noted that its depressed sales and earnings in the third quarter were consistent with broader industry trends affecting U.S. chemical companies, which experienced weak China demand, continued destocking, and tariffs.

Stakeholder Impact

• Shareholders will experience reduced earnings per share ($0.06 for Q3 2025 vs $0.19 for Q3 2024; $0.32 for 9M 2025 vs $0.60 for 9M 2024).
• Customers of cosmetic ingredients may see changes in pricing from Ashland Specialty Ingredients as they aim to regain market share.
• Employees may face pressure if sales declines persist, though no specific impact was mentioned.

Next Steps

• Continue working with an outside pharmaceutical consultant to include Renacidin on additional drug formularies.
• Implement new marketing agreements for personal care products to increase revenue.
• Ashland Specialty Ingredients (ASI) plans to offer more competitive pricing to regain market share.

Key Dates

Recommendation

The significant decline in sales and net income for both the quarter and nine-month period indicates a challenging operating environment, primarily driven by external factors affecting the cosmetic ingredients segment. While the current financial performance is poor, the company has identified the root causes (tariffs, geopolitical issues, destocking impacting ASI) and is actively pursuing strategies to mitigate these, such as increasing pharmaceutical sales (Renacidin project) and securing new marketing agreements for personal care products. The increase in pharmaceutical and medical product sales offers a glimmer of resilience. Given the identified challenges and the proactive steps being taken, a 'hold' recommendation is appropriate, suggesting investors monitor the effectiveness of these strategic initiatives before making further investment decisions.

Keywords

Cosmetic Ingredients, Pharmaceuticals, Medical Lubricants, Sexual Wellness Ingredients, Earnings Report, Q3 2025, Net Sales, Net Income, EPS, Ashland Specialty Ingredients, Renacidin, Tariffs, Geopolitical Concerns, Destocking